Alterity completes Phase 2 trial in multiple system atrophy
Alterity Therapeutics (ASX:ATH) has announced the completion of the Phase 2 clinical trial in multiple system atrophy (MSA) for its lead drug candidate, ATH434. No results were released, but Alterity plans to release topline results in late January or early February 2025. “We are very excited to announce that the last participant in our Phase 2 study […]
Alterity completes Phase 2 trial in multiple system atrophy Read More »